Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Oral tranexamic acid safe, effective for moderate-to-severe melasma

31 Jan 2018

Oral tranexamic acid (TA) may help improve moderate-to-severe melasma with negligible side effects, according to a recent study.

Of the 44 patients included, 39 completed the study. Reduction in the modified Melasma Area and Severity Index (mMASI) score at 3 months was greater in the TA group than in the control group (49 percent vs 18 percent). Patients with severe melasma benefitted more from treatment than those with moderate melasma.

Three months after treatment cessation, reduction in mMASI score remained higher in the TA cohort compared with the baseline visit vs that in the placebo arm (26 percent vs 19 percent). There were no adverse events in either group.

This single-centre study enrolled predominantly Hispanic women. Patients with moderate-to-severe melasma received 250-mg TA or placebo capsules twice daily for 3 months and sunscreen, followed by 3 months of treatment with sunscreen only. The mMaSI score was the primary outcome measure.

In another study, researchers concluded that topical TA was effective for melasma, adding that suppression of endothelin-1 could be one of the mechanisms of action of TA on melasma. [Clin Exp Dermatol 2016;41:480-485]

A recent systematic review and meta-analysis has shown that TA is effective and safe, either alone or as an adjuvant to routine treatment modalities for melasma. [Acta Derm Venereol 2017;97:776-781]

“Melasma is a common pigmentary disorder that is often difficult to treat,” according to the investigators of the current study. “TA has emerged as a promising treatment for melasma; however, few controlled studies exist.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.